口服氟嘧啶类药物的比较药理学：聚焦于药代动力学、药效学及药物调节作用
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
作者信息
Milano G, Ferrero J-M, François E
机构信息
Oncopharmocology Unit, Centre Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France.
出版信息
Br J Cancer. 2004 Aug 16;91(4):613-7. doi: 10.1038/sj.bjc.6601973.
Abstract
The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability. Oral fluoropyrimidines differ particularly as concerns their pharmacokinetic profile and especially in the delivery of circulating 5-FU. More clinical studies need to be performed incorporating tumour predictive markers during oral fluoropyrimidine-based treatment. The new possibilities are to achieve pharmacomodulation of oral fluoropyrimidines, notably for UFT and capecitabine, that open up the prospect of establishing significant novel treatment protocols based on drug combinations.
摘要
本综述文章的主要目的是通过强调不同的5-氟尿嘧啶（5-FU）前药在代谢活化、二氢嘧啶脱氢酶抑制、药代动力学特征和生物调节能力方面各自的药理学特性，来阐明这些前药。口服氟嘧啶在药代动力学特征方面存在差异，尤其是在循环5-FU的递送方面。在基于口服氟嘧啶的治疗过程中，需要进行更多纳入肿瘤预测标志物的临床研究。新的可能性在于实现口服氟嘧啶的药物调节，特别是对于优福定（UFT）和卡培他滨，这为基于药物组合建立重要的新型治疗方案开辟了前景。
相似文献
1
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.口服氟嘧啶类药物的比较药理学：聚焦于药代动力学、药效学及药物调节作用
Br J Cancer. 2004 Aug 16;91(4):613-7. doi: 10.1038/sj.bjc.6601973.
2
The oral fluoropyrimidines in cancer chemotherapy.癌症化疗中的口服氟嘧啶类药物。
Clin Cancer Res. 1999 Sep;5(9):2289-96.
3
The oral fluorinated pyrimidines.口服氟嘧啶类药物。
Invest New Drugs. 2001;19(1):41-59. doi: 10.1023/a:1006404701008.
4
5
Novel oral chemotherapy agents.新型口服化疗药物。
Curr Oncol Rep. 2000 Jan;2(1):31-7. doi: 10.1007/s11912-000-0008-x.
6
Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil?口服氟嘧啶类药物：它们等同于肠外输注的5-氟尿嘧啶吗？
Cancer Invest. 2001;19(8):854-7. doi: 10.1081/cnv-100107747.
7
Oral therapy for colorectal cancer: how to choose.结直肠癌的口服治疗：如何选择。
Oncology (Williston Park). 2000 Jun;14(6):799-807; discussion 807-8, 813-4,.
8
Oral fluoropyrimidine treatment of colorectal cancer.口服氟嘧啶治疗结直肠癌。
Clin Colorectal Cancer. 2001 Aug;1(2):95-103. doi: 10.3816/CCC.2001.n.009.
9
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.门诊化疗的新选择——口服氟嘧啶类药物的作用
Cancer Treat Rev. 2001 Aug;27(4):211-20. doi: 10.1053/ctrv.2001.0229.
10
Oral DPD-inhibitory fluoropyrimidine drugs.口服二氢嘧啶脱氢酶（DPD）抑制性氟嘧啶类药物。
Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):19-23.
引用本文的文献
1
De-Escalating Anticancer Treatment: Watch Your Step.降低抗癌治疗强度：谨慎行事。
Cancers (Basel). 2025 Jul 26;17(15):2474. doi: 10.3390/cancers17152474.
2
Capecitabine-induced Subacute Cutaneous Lupus Erythematosus.卡培他滨诱导的亚急性皮肤型红斑狼疮
An Bras Dermatol. 2019 Sep-Oct;94(5):618-619. doi: 10.1016/j.abd.2019.09.004. Epub 2019 Sep 30.
3
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.卡培他滨节拍化疗治疗难治性转移性结直肠癌患者的药代动力学分析。
Invest New Drugs. 2018 Aug;36(4):709-714. doi: 10.1007/s10637-018-0579-8. Epub 2018 Feb 27.
4
Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy.结直肠癌中有机阴离子转运体2和还原型叶酸载体1的免疫组化分析：作为口服尿嘧啶/替加氟加亚叶酸化疗反应预测指标的意义
Mol Clin Oncol. 2013 Jul;1(4):661-667. doi: 10.3892/mco.2013.104. Epub 2013 Apr 15.
5
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.口服S-1可抑制转移性乳腺癌患者循环内皮细胞计数。
Int J Clin Oncol. 2014;19(3):452-9. doi: 10.1007/s10147-013-0570-5. Epub 2013 Jun 6.
6
Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.晚期胃癌或胃食管结合部腺癌系统化疗安全性和有效性的地域差异：一项荟萃分析和荟萃回归。
Gastric Cancer. 2012 Jul;15(3):265-80. doi: 10.1007/s10120-012-0151-8. Epub 2012 May 12.
7
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.多因素药物遗传学分析在接受氟尿嘧啶为基础的治疗联合西妥昔单抗伊立替康治疗的结直肠癌患者中的应用。
Br J Clin Pharmacol. 2012 May;73(5):776-85. doi: 10.1111/j.1365-2125.2011.04141.x.
8
Personalized colon cancer care in 2010.2010 年的个性化结肠癌治疗。
Semin Oncol. 2011 Apr;38(2):284-308. doi: 10.1053/j.seminoncol.2011.01.001.
9
Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.结直肠癌的药物基因组学：个体化治疗的第一步。
World J Gastroenterol. 2007 Nov 28;13(44):5888-901. doi: 10.3748/wjg.v13.i44.5888.
10
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.替加氟-尿嘧啶（UFT）联合亚叶酸钙以新的每日两次口服给药方案进行的临床药代动力学分析。
Clin Pharmacokinet. 2007;46(11):953-63. doi: 10.2165/00003088-200746110-00003.
本文引用的文献
1
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.卡培他滨-顺铂联合用药在头颈癌患者中的Ⅰ期及药代动力学研究。
Ann Oncol. 2003 Oct;14(10):1578-86. doi: 10.1093/annonc/mdg410.
2
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.一种肿瘤选择性二氢嘧啶脱氢酶抑制剂RO0094889增强卡培他滨的抗肿瘤活性
Int J Cancer. 2003 Sep 20;106(5):799-805. doi: 10.1002/ijc.11276.
3
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.口服优福定后替加氟和5-氟尿嘧啶药代动力学的建模：30例晚期乳腺癌患者的群体研究。
Cancer Chemother Pharmacol. 2003 Aug;52(2):99-107. doi: 10.1007/s00280-003-0616-x. Epub 2003 May 27.
4
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.替加氟、奥替拉西钾和5-氯-2,4-二羟基吡啶口服制剂S-1（摩尔比1:0.4:1）在实体瘤患者中的药代动力学。
Cancer Chemother Pharmacol. 2003 Jul;52(1):1-12. doi: 10.1007/s00280-003-0617-9. Epub 2003 May 9.
5
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.卡培他滨及其代谢产物在晚期乳腺癌患者恶性组织和健康组织中的渗透情况。
Br J Cancer. 2003 Mar 10;88(5):782-7. doi: 10.1038/sj.bjc.6600809.
6
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.二氢嘧啶脱氢酶（DPD）抑制剂RO0094889的肿瘤激活前药的设计与合成，用于与卡培他滨联合治疗。
Bioorg Med Chem Lett. 2003 Mar 10;13(5):867-72. doi: 10.1016/s0960-894x(02)01082-x.
7
Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.原发性肿瘤中二氢嘧啶脱氢酶和胸苷酸合成酶基因表达的联合作为转移性结直肠癌氟嘧啶类化疗疗效的预测参数。
Clin Cancer Res. 2003 Feb;9(2):786-91.
8
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.在接受过蒽环类药物治疗的晚期乳腺癌患者中，卡培他滨联合多西他赛的联合疗法具有更好的生存率：III期试验结果
J Clin Oncol. 2002 Jun 15;20(12):2812-23. doi: 10.1200/JCO.2002.09.002.
9
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.食物对口服5-氟尿嘧啶与乙磺酰尿联合应用时处置过程影响的评估。
Cancer Chemother Pharmacol. 2002 May;49(5):398-402. doi: 10.1007/s00280-002-0431-9. Epub 2002 Feb 23.
10
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.肾功能损害对卡培他滨（希罗达）在癌症患者体内药代动力学及耐受性的影响。
Cancer Chemother Pharmacol. 2002 Mar;49(3):225-34. doi: 10.1007/s00280-001-0408-0. Epub 2002 Jan 10.
Zotero 插件